#USA #Florida Cancer Specialists #Fort Myers #Blood Cancer #oncology research

Florida Cancer Specialists Present Blood Cancer Research at Major Summit

Florida Cancer Specialists & Research Institute (FCS) has made waves in the oncology community with its latest research that will be showcased at the MOASC 2025 Annual Oncology Summit and Research Symposium. The summit will feature a significant presentation from Amanda Warner, MS, RN, the Director of Real-World Evidence at FCS. She will unveil key findings from a study entitled "Management of Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) in a Large US Community Oncology Practice: A Focus on Patient Outcomes Post Erythropoiesis-Stimulating Agent (ESA) Treatment."

The research was co-authored by notable FCS physicians and leaders, including Lucio N. Gordan, MD, FCS President and Managing Physician, and Gustavo Fonseca, MD, FACP, a renowned medical oncologist within the institute. Their collaborative efforts aim to shed light on the treatment of lower-risk myelodysplastic syndromes, which involve improper bone marrow functioning.

The focus of the study, evidenced by real-world data from over 350,000 patients treated at FCS annually, showcases the clinic’s innovative approach toward addressing anemia related to myelodysplastic syndromes through established Erythropoiesis-Stimulating Agents. Dr. Gordan emphasized the value of real-world evidence, noting that it significantly enriches the clinical trials process and assists in the discovery and development of new therapies.

The Importance of Real-World Evidence

The research highlights how real-world evidence contributes not just to clinical outcomes but also aids in advancing the understanding of hematologic diseases and other cancer types. With the growing importance of precision oncology, FCS continues to pave the way for enhanced treatment plans utilizing cutting-edge technologies and methodologies.

The FCS Real-World Evidence team excels at delivering clinical insights, facilitating everything related to study types from preliminary consultations and study designs to the meticulous review of clinical endpoints. By maintaining a high standard of quality and integrity in their research, they strive to produce impactful insights in oncology.

The MOASC 2025 Annual Oncology Summit

The MOASC (Medical Oncology Association of Southern California) is a key affiliate of the Association of Clinical Oncology (ASCO). Their annual summit serves as a platform for oncology professionals to discuss the latest advancements, technologies, therapeutic agents, and diagnostic tools in the field of cancer care.

In this year’s symposium, experts will come together to share knowledge and insights on the advancements made in cancer care, emphasizing the crucial role of continued research and collaboration among professionals.

Overall, the participation of Florida Cancer Specialists at this prestigious event reflects their commitment to optimally advancing the field of oncology, enhancing patient care, and exploring innovative therapeutic solutions.

FCS's extensive history of over 40 years has established them as innovators in cancer treatment and research. The institute not only offers patients access to groundbreaking clinical trials but also positions itself as a leader among private oncology practices in Florida and nationwide. A significant number of new cancer drugs in the U.S. are made available to patients through clinical trials at FCS, often prior to FDA approval. Their dedicated team of physicians is committed to applying modern precision oncology methods, ensuring customized treatment plans that focus on improving patient outcomes.